Achieve Life Sciences (ACHV) CMO discloses options and 39,600 shares

Rhea-AI Filing Summary

Achieve Life Sciences Chief Medical Officer Mark Rubinstein filed an initial Form 3 showing his beneficial ownership in the company. As of the event date, he directly holds 39,600 shares of common stock. He also holds stock options to purchase 47,000 shares at $4.52 per share, which became 25% exercisable on September 30, 2025 with the remainder vesting in 36 equal monthly installments, and options to purchase 50,000 shares at $3.10 per share, with 25% becoming exercisable on October 7, 2026 and the rest vesting in 36 equal monthly installments thereafter.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rubinstein Mark Lawrence

(Last) (First) (Middle)

22722 29TH DR. SE

SUITE 100

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2026

3. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	39,600	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	12/06/2034	Common Stock	47,000	$4.52	D
Stock Option (right to buy)	(2)	10/01/2035	Common Stock	50,000	$3.1	D

Explanation of Responses:

1. 25% of the options became exercisable on September 30, 2025 and the remainder vest in thirty-six equal monthly installments thereafter.

2. 25% of the options become exercisable on October 7, 2026 and the remainder vest in thirty-six equal monthly installments thereafter.

	/s/ Sandra Thomson as attorney-in-fact for Mark Rubinstein	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filing show for ACHV Chief Medical Officer Mark Rubinstein?

The Form 3 shows that Chief Medical Officer Mark Rubinstein beneficially owns 39,600 shares of Achieve Life Sciences common stock and holds two stock option awards for additional shares.

How many ACHV common shares does Mark Rubinstein currently own directly?

Mark Rubinstein directly owns 39,600 shares of Achieve Life Sciences common stock as reported in Table I of the Form 3.

What stock options does Mark Rubinstein hold in Achieve Life Sciences (ACHV)?

He holds two stock option grants: one for 47,000 shares at $4.52 per share expiring on December 6, 2034, and another for 50,000 shares at $3.10 per share expiring on October 1, 2035, both held directly.

How do Mark Rubinstein’s 47,000-share ACHV stock options vest?

For the 47,000-share stock option, 25% became exercisable on September 30, 2025, and the remaining 75% vest in thirty-six equal monthly installments after that date.

What is the vesting schedule for Mark Rubinstein’s 50,000-share ACHV option grant?

For the 50,000-share stock option, 25% become exercisable on October 7, 2026, with the remaining 75% vesting in thirty-six equal monthly installments thereafter.

Is Mark Rubinstein’s ownership in ACHV held directly or through another entity?

The Form 3 reports that both the 39,600 common shares and the stock options are held with direct (D) ownership, with no indirect ownership entity indicated.